Business Description
Botanix Pharmaceuticals Ltd
NAICS : 325412
SIC : 2834
ISIN : AU000000BOT2
Total Employee Number:
1Description
Botanix Pharmaceuticals Ltd is a pharmaceutical company. It launched Sofdra (sofpironium) topical gel, 12.45%, a prescription anticholinergic medicine used topically to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children 9 years of age and older. Its mechanism of action targets the M3 receptor in the sweat gland, blocking acetylcholine to reduce sweat at its source. Its segments include Australia and United States which generates all of the revenue.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.42 | |||||
Equity-to-Asset | 0.6 | |||||
Debt-to-Equity | 0.41 | |||||
Debt-to-EBITDA | -0.4 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -3.73 | |||||
Beneish M-Score | 0.95 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -55.4 | |||||
3-Year EPS without NRI Growth Rate | -58.7 | |||||
3-Year FCF Growth Rate | -20.8 | |||||
3-Year Book Growth Rate | 10.6 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 85.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 8.52 | |||||
9-Day RSI | 21.46 | |||||
14-Day RSI | 30.26 | |||||
3-1 Month Momentum % | -8.7 | |||||
6-1 Month Momentum % | -55.32 | |||||
12-1 Month Momentum % | -83.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.59 | |||||
Quick Ratio | 1.58 | |||||
Cash Ratio | 1.18 | |||||
Days Inventory | 738.18 | |||||
Days Sales Outstanding | 73.58 | |||||
Days Payable | 246.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -27.7 | |||||
Shareholder Yield % | -102.85 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 57.61 | |||||
Operating Margin % | -205.05 | |||||
Net Margin % | -206.4 | |||||
EBITDA Margin % | -191.16 | |||||
FCF Margin % | -187.17 | |||||
OCF Margin % | -187.17 | |||||
ROE % | -105.28 | |||||
ROA % | -62.73 | |||||
ROIC % | -134.39 | |||||
3-Year ROIIC % | -140.13 | |||||
ROC (Joel Greenblatt) % | -275.84 | |||||
ROCE % | -80.29 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 30 | |||||
PS Ratio | 1.2 | |||||
PB Ratio | 0.79 | |||||
Price-to-Tangible-Book | 1.8 | |||||
EV-to-EBIT | -0.57 | |||||
EV-to-Forward-EBIT | -1.2 | |||||
EV-to-EBITDA | -0.6 | |||||
EV-to-Forward-EBITDA | -1.2 | |||||
EV-to-Revenue | 1.14 | |||||
EV-to-Forward-Revenue | 0.71 | |||||
EV-to-FCF | -0.64 | |||||
| Price-to-Net-Current-Asset-Value | 1.8 | |||||
Earnings Yield (Greenblatt) % | -175.62 | |||||
FCF Yield % | -131.14 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Botanix Pharmaceuticals Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 34.513 | ||
| EPS (TTM) (A$) | -0.032 | ||
| Beta | 0.4571 | ||
| 3-Year Sharpe Ratio | -0.71 | ||
| 3-Year Sortino Ratio | -0.82 | ||
| Volatility % | 63.19 | ||
| 14-Day RSI | 30.26 | ||
| 14-Day ATR (A$) | 0.001376 | ||
| 20-Day SMA (A$) | 0.02005 | ||
| 12-1 Month Momentum % | -83.85 | ||
| 52-Week Range (A$) | 0.018 - 0.17 | ||
| Shares Outstanding (Mil) | 2,736.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Botanix Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Botanix Pharmaceuticals Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| 0.333333:1 Stock Split | 2016-06-16 | 0.02 (+0.00%) | ||
| 0.02:1 Stock Split | 2014-01-24 | 0.15 (+0.00%) | ||
| 0.25:1 Stock Split | 2004-08-23 | 114.00 (+0.00%) | ||
| 0.333333:1 Stock Split | 2001-07-31 | 117.00 (+0.00%) | ||
| 1.00432:1 Stock Split | 1994-11-16 | 2,509.17 (+0.00%) |
Show
Entries
Botanix Pharmaceuticals Ltd Frequently Asked Questions
What is Botanix Pharmaceuticals Ltd(ASX:BOT)'s stock price today?
The current price of ASX:BOT is A$0.02. The 52 week high of ASX:BOT is A$0.17 and 52 week low is A$0.02.
When is next earnings date of Botanix Pharmaceuticals Ltd(ASX:BOT)?
The next earnings date of Botanix Pharmaceuticals Ltd(ASX:BOT) is .
Does Botanix Pharmaceuticals Ltd(ASX:BOT) pay dividends? If so, how much?
Botanix Pharmaceuticals Ltd(ASX:BOT) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Botanix | World First Human Clinical Study Shows Synthetic CBD Formula Eradicates Staphylococcus Aureus | 2021-02-02 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers